NEUSTAR
Neustar® , Inc., a global information services company and leader in identity resolution, today announced the release of UltraThreat Feeds, a new service that provides its enterprise customers with access to real-time threat data to help them better identify cyber threats as they evolve. Designed by Neustar’s renowned security experts and leading academic researchers, the service – unique to Neustar – enables security and threat intelligence teams of all sizes to access threat feeds based on analysis and observations curated from Neustar’s expansive DNS, OneID and IP decisioning data.
Incorporating proprietary data derived from Neustar’s Security Portfolio & OneID identity resolution platform, UltraThreat Feeds can be ingested into a client’s existing platform to deliver superior threat data and provide valuable insights to unique and developing threats in near real-time.
“With the average cost of a data breach now at nearly $4 million, enterprises are investing significant resources into threat intelligence solutions to better defend themselves. A key change is enabling network and application security tools with improved real-time awareness of active threats,” said Rodney Joffe, security CTO, senior technologist and fellow at Neustar. “For example, SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls all require threat data to power their security functions to detect and block malicious actors. Neustar’s UltraThreat Feeds service delivers deep, rich threat data, giving users the power to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks.”
UltraThreat Feeds enable Neustar customers to identify:
- Malicious Domain Generation Algorithms (“DGAs”) – When malicious actors register one of the thousands of domains that are created by the DGAs within their malware, and that then allow the actors to control infected hosts from their Command and Control Servers (C2).
- Suspicious DNS Tunneling Attempts – When Domains leverage the DNS protocol to create a “tunnel” to exfiltrate data past customers’ security measures.
- Newly Observed Domains – When a Domain with little or no history is suddenly active, which presents increased risk.
- Domain Updates (Nameserver or Hosting IP Address) – When there are indications that a domain has been hijacked.
- Domain Spoofing (Business Email Compromise) – When fake online personas trick victims into making fraudulent transactions by imitating or resembling legitimate domains.
Neustar’s UltraThreat Feeds service has an advantage over competitors, thanks to the availability of its own unique data assets, including DNS data exhaust collected from the more than 100 billion queries received from 30 globally distributed nodes every day and supplemented by the IP address intelligence and analytics processed across Neustar’s product suite. Combined with behavioural analysis and pattern-based research, this advantage enables Neustar to derive truly unique insights into malicious activity. With insight gained from Neustar’s globally distributed authoritative and recursive DNS network, Neustar OneID, IP Intelligence geolocation and risk data, UltraThreat Feeds can provide a proprietary view of global threats to help identify and stop bad traffic, both inbound and outbound.
"With increasing attacker sophistication, and renewed aggression from nation-state adversaries focused on corporate espionage, many organisations are trying to find out how to properly leverage these [threat intelligence] services to protect themselves," wrote Forrester analysts Josh Zelonis and Joseph Blankenship in the report, The Forrester Tech Tide™: Zero Trust Threat Detection And Response, Q1 2019.
For more technical details on Neustar UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultra-threat-detection-feeds .
-ENDS-
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: www.home.neustar .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
